Mr. Fabio Chianelli reports

PHARMATHER UPDATES STRATEGY ON PERSONALIZED MEDICINES FOR PEPTIDES AND PSYCHEDELICS

Pharmather Holdings Ltd. is providing a corporate update outlining its strategic focus on personalized medicines -- specifically peptides and psychedelics.

Pharmather believes peptides and psychedelics are gaining strong momentum and plans to capitalize on this opportunity using its Medbotx 3-D-printing platform and artificial-intelligence-driven formulation tools. The company's main focus is personalized medicines, aiming to develop treatments tailored to individual patient needs.

"Medicine is shifting toward treatments tailored to each patient," said Fabio Chianelli, chairman and chief executive officer of Pharmather. "We see peptides and psychedelics as key growth areas and aim to position Pharmather at the forefront of personalized health-care using AI and advanced manufacturing."

One platform, two emerging therapeutic categories

Pharmather's personalized-medicine strategy will initially focus on two therapeutic categories -- personalized peptides and personalized psychedelics.

Personalized peptides

Peptides are gaining strong interest, but traditional manufacturing often cannot deliver personalized doses or flexible formats. Pharmather aims to solve this using its Medbotx 3-D-printing platform and AI to create customized peptide products, including tailored doses, combination therapies, controlled-release options, and multiple formats such as tablets, films, gels and patches.

The U.S. Food and Drug Administration's pharmacy compounding advisory committee is scheduled to meet on July 23 and July 24, 2026, to consider several peptide-related bulk drug substances for potential inclusion on the Section 503A Bulks List. The substances include BPC-157, KPV, TB-500, MOTS-C, emideltide, Semax and Epitalon. The meeting reflects increased formal regulatory attention to peptides, although there can be no assurance that the advisory committee will recommend, or the FDA will approve, the inclusion of any substance on the 503A Bulks List.

Pharmather believes that greater regulatory clarity could create opportunities for compliant pharmaceutical development, compounding, patient-specific formulation and advanced manufacturing technologies.

Personalized psychedelics

Pharmather also plans to apply its personalized-medicine platform to psychedelics, where precise dosing and tailored delivery are important, and believes its 3-D printing and AI capabilities can offer a way to develop these therapies.

The regulatory environment for psychedelic drug development is improving. In July, 2026, the FDA issued its first guidance on clinical studies for psychedelic drugs, helping define how treatments for mental health and substance-use disorders can be developed. The FDA has also issued priority vouchers to companies and has publicly supported the advancement of psychedelic therapies. In addition, the U.S. Department of Health and Human Services and Department of Veterans Affairs announced a five-year collaboration to support research and the potential future use of FDA-approved psychedelic treatments for veterans.

These developments do not constitute regulatory approval of any psychedelic product. However, Pharmather believes they demonstrate growing institutional support for the responsible investigation and development of psychedelic medicines.

Powered by Medbotx and Artificial Intelligence

Medbotx is Pharmather's robotic 3-D-printing platform, developed for personalized medicines. The platform is intended to provide key product characteristics, potentially including:

Immediate, sustained or delayed release;

Multiple release phases within one product;

Patient-specific dosing;

Alternative pharmaceutical delivery formats.

The company intends to continue advancing Medbotx as a core component of its personalized-medicine strategy, with a focus on integrating formulation development, manufacturing capabilities and scalable applications to support future commercialization efforts.

Pharmather's commercialization strategy and priorities

Pharmather intends to pursue a capital-efficient business model that may include:

• Developing proprietary peptide and psychedelic formulations;

• Entering partnerships with 503A compounding pharmacies, hospitals and research institutions;

• Collaborating with pharmaceutical and biotechnology companies;

• Supplying Medbotx systems, formulation inputs and related consumables;

• Participating in the commercialization of selected personalized-medicine products.

"Our vision is to position Pharmather at the forefront of personalized medicine, where innovation in peptides, psychedelics and advanced manufacturing can meaningfully improve patient outcomes," concluded Mr. Chianelli.

About Pharmather Holdings Ltd.

Pharmather Holdings is a specialty pharmaceutical company focused on personalized medicines, specifically peptides and psychedelics.

We seek Safe Harbor.